Progress and challenges in the adjuvant treatment of stage II and III colon cancers
摘要：
Whereas the benefit of adjuvant 5-fluorouracil and leucovorin have been well established in resected stage III colon cancer, a significant benefit for patients with stage II disease has been more difficult to demonstrate. More recently, oxaliplatin-based chemotherapy with regimens such as oxaplatin plus 5-fluorouracil/leucovorin have been shown to improve disease-free and overall survival in these stage III patients. This review will discuss the development of adjuvant chemotherapy in colon cancer, focusing on recent progress and particular topical issues related to its use in this disease, such as the use of surrogate end points for overall survival in contemporary clinical trials.
展开
关键词：
Humans Colonic Neoplasms Antineoplastic Agents Antimetabolites, Antineoplastic Disease-Free Survival Chemotherapy, Adjuvant Drug Administration Schedule Survival Rate Antibodies, Monoclonal Neoplasm Staging
DOI：
10.1586/14737140.8.4.595
被引量：
年份：
2008
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
